Proteolytic Cleavages in the VEGF Family: Generating Diversity among Angiogenic VEGFs, Essential for the Activation of Lymphangiogenic VEGFs by Künnapuu, Jaana et al.
biology
Review
Proteolytic Cleavages in the VEGF Family: Generating
Diversity among Angiogenic VEGFs, Essential for
the Activation of Lymphangiogenic VEGFs




Bokharaie, H.; Jeltsch, M. Proteolytic
Cleavages in the VEGF Family:
Generating Diversity among
Angiogenic VEGFs, Essential for
the Activation of Lymphangiogenic
VEGFs. Biology 2021, 10, 167.
https://doi.org/10.3390/
biology10020167
Academic Editor: Hang Fai Kwok
Received: 15 January 2021
Accepted: 18 February 2021
Published: 23 February 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Drug Research Program, Faculty of Pharmacy, University of Helsinki, 00014 Helsinki, Finland;
jaana.vulli@helsinki.fi (J.K.); honey.bokharaie@helsinki.fi (H.B.)
2 Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, 00014 Helsinki,
Finland
3 Wihuri Research Institute, 00290 Helsinki, Finland
* Correspondence: michael@jeltsch.org; Tel.: +358-50-3200235
Simple Summary: Vascular endothelial growth factors (VEGFs) regulate the growth of blood and
lymphatic vessels. Some of them induce the growth of blood vessels, and others the growth of
lymphatic vessels. Blocking VEGF-A is used today to treat several types of cancer (“antiangiogenic
therapy”). However, in other diseases, we would like to increase the activity of VEGFs. For example,
VEGF-A could generate new blood vessels to protect from heart disease, and VEGF-C could generate
new lymphatics to counteract lymphedema. Clinical trials are testing the latter concept at the moment.
Because VEGF-C and VEGF-D are produced as inactive precursors, we propose that novel drugs
could also target the enzymatic activation of VEGF-C and VEGF-D. However, because of the delicate
balance between too much and too little vascular growth, a detailed understanding of the activation
of the VEGFs is needed before such concepts can be converted into safe and efficacious therapies.
Abstract: Specific proteolytic cleavages turn on, modify, or turn off the activity of vascular endothelial
growth factors (VEGFs). Proteolysis is most prominent among the lymphangiogenic VEGF-C and
VEGF-D, which are synthesized as precursors that need to undergo enzymatic removal of their C-
and N-terminal propeptides before they can activate their receptors. At least five different proteases
mediate the activating cleavage of VEGF-C: plasmin, ADAMTS3, prostate-specific antigen, cathepsin
D, and thrombin. All of these proteases except for ADAMTS3 can also activate VEGF-D. Process-
ing by different proteases results in distinct forms of the “mature” growth factors, which differ
in affinity and receptor activation potential. The “default” VEGF-C-activating enzyme ADAMTS3
does not activate VEGF-D, and therefore, VEGF-C and VEGF-D do function in different contexts.
VEGF-C itself is also regulated in different contexts by distinct proteases. During embryonic de-
velopment, ADAMTS3 activates VEGF-C. The other activating proteases are likely important for
non-developmental lymphangiogenesis during, e.g., tissue regeneration, inflammation, immune
response, and pathological tumor-associated lymphangiogenesis. The better we understand these
events at the molecular level, the greater our chances of developing successful therapies targeting
VEGF-C and VEGF-D for diseases involving the lymphatics such as lymphedema or cancer.
Keywords: vascular endothelial growth factors (VEGFs); VEGF-A; PlGF; VEGF-B; VEGF-C; VEGF-
D; angiogenesis; lymphangiogenesis; CCBE1; proteases; ADAMTS3; plasmin; cathepsin D; KLK3;
prostate-specific antigen (PSA); thrombin; wound healing; metastasis; proteolytic activation; vascular
biology; lymphedema
1. Introduction
In vertebrates, the family of vascular endothelial growth factors (VEGFs) typically
comprises five genes: VEGF-A (in older literature often referred to simply as “VEGF”),
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placenta growth factor (PlGF), VEGF-B, VEGF-C, and VEGF-D. In addition to these ortho-
dox VEGFs, several genes coding for VEGF-like molecules have been discovered in some
members of the poxvirus and iridovirus families (collectively named VEGF-E) [1–4] and
in venomous reptiles (collectively named VEGF-F) [5]. In vertebrates, the VEGF growth
factors are central to the development and maintenance of the cardiovascular system
and the lymphatic system. Non-vertebrates also feature VEGF-like molecules, but their
functions are less well defined.
The subdivision of the vertebrate vascular system into the cardiovascular and the lym-
phatic system is reflected at the molecular level by a subdivision of the VEGF family
into VEGFs acting primarily on blood vessels (VEGF-A, PlGF, and VEGF-B) and VEGFs
acting mostly on lymphatic vessels (VEGF-C and VEGF-D). This specificity results from
the expression pattern of the three VEGF receptors (VEGFRs). VEGFR-1 and VEGFR-2 are
expressed on blood vascular endothelial cells (BECs), while lymphatic endothelial cells
(LECs) express VEGFR-2 and VEGFR-3 (Figure 1).
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Figure 1. Vascular endothelial growth factors (VEGFs) act on blood vessels and/or lymphatic vessels 
depending on their affinities towards VEGF receptors 1, -2, and -3. VEGFR-2 is expressed on both 
blood and lymphatic endothelium. In principle, growth factors that do activate VEGFR-2 can 
promote both the growth of blood vessels (angiogenesis) and lymphatic vessels 
(lymphangiogenesis). VEGF-E and VEGF-F are not of human origin: VEGF-E genes are found in 
viral genomes, and VEGF-F is a snake venom component. All receptor-growth factor interactions 
require the extracellular domain 2 of the VEGF receptors (shown in yellow) [6–9]. Domain 3 of 
VEGFR-2 is important for the interaction of VEGFR-2 with both VEGF-A [7] and VEGF-C [8], and 
domain 1 of VEGFR-3 is important for the interaction of VEGF-C with VEGFR-3 [9]. 
The biology of the VEGFs and their signaling pathways has been extensively 
discussed elsewhere [10,11]. From all VEGF family members, only VEGF-A and VEGF-C 
are essential in the sense that constitutive ablation of their genes in mice results in 
embryonic lethality [12–14]. VEGF-A levels are so crucial that even heterozygous mice are 
not viable. In fact, VEGFA was the first gene where the deletion of a single allele was 
shown to be embryonically lethal [12,13]. While the primary function and importance of 
Figure 1. Vascular endothelial growth factors (VEGFs) act on blood vessels and/or lymphatic vessels
depending on their affinities towards VEGF receptors 1, -2, and -3. VEGFR-2 is expressed on both
blood and lymphatic endothelium. In principle, growth factors that do activate VEGFR-2 can promote
both the growth of blood vessels (angiogenesis) and lymphatic vessels (lymphangiogenesis). VEGF-E
and VEGF-F are not of human origin: VEGF-E genes are found in viral genomes, and VEGF-F is
a snake venom component. All receptor-growth factor interactions require the extracellular domain 2
of the VEGF rece tors (sh wn in yellow) [6–9]. Domain 3 of VEGFR-2 is important for the interactio
of VEGFR-2 with both VEGF-A [7] and VEGF-C [8], and domain 1 of FR-3 is important for
the interaction of VEGF-C with VEGFR-3 [9].
The biology of the VEGFs and their signaling pathways has been extensively dis-
cussed elsewhere [10,11]. From all VEGF family members, only VEGF-A and VEGF-C are
essential in the sense that constitutive ablation of their genes in mice results in embryonic
lethality [12–14]. VEGF-A levels are so crucial that even heterozygous mice are not viable.
In fact, VEGFA was the first gene where the deletion of a single allele was shown to be
embryonically lethal [12,13]. While the primary function and importance of the cardiovas-
cular system are also obvious to the layperson, the tasks of the lymphatic system escape
even some life science professionals. Its major three tasks are:
1. Tissue drainage for fluid balance and waste disposal
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2. Immune surveillance, including hosting and trafficking of immune cells
3. Uptake of dietary long-chain fatty acids and other highly lipophilic compounds
in the intestine
Considerable effort has been devoted to the mechanisms and effects of receptor
binding and downstream signaling of the VEGFs. Less is known about the processes
upstream of receptor binding such as secretion, release, and proteolytic processing. In this
review, we want to briefly give an overview of what is known about the proteolytic
processing of VEGFs with a focus on the lymphangiogenic VEGFs.
Evolutionarily, the importance of proteases has been remarkable. Proteolytic process-
ing often regulates protein activity and creates variation in a protein’s function. This has
been suggested by phylogenetic and functional studies in all kingdoms of life, including
viruses [15], plants [16], and animals [17]. Not surprisingly, proteases are used to regulate
function and create functional variety in the VEGF family and can be regarded as signaling
molecules [18].
2. Proteolytic Processing of the Hemangiogenic VEGFs
Among the hemangiogenic VEGFs, protein diversification within a single VEGF
family member relies more on differential mRNA splicing than on proteolytic process-
ing (Figure 2; reviewed in [19]). mRNA splicing generates several isoforms of VEGF-A,
which differ by the extent of the C-terminal, predominantly basic heparin-binding domain
(HBD) [20–22]. The HBD mediates the interaction of VEGF-A with the extracellular matrix
(ECM), cell surface heparan sulfate proteoglycans (HSPGs), and neuropilin-1. The interac-
tion with HSPGs involves both a sequence-specific binding epitope and electrostatic effects
of a predominantly basic amino acid sequence. Only a few isoforms are entirely devoid
of heparin-binding properties under physiological conditions and therefore fully soluble.
Mice expressing only the major soluble isoform (VEGF-A121) are born but show severe
cardiovascular defects and die from cardiac failure [23].
The matrix-binding properties of the larger VEGF-A isoforms are essential for gen-
erating growth factor gradients, which are assumed to be essential for efficient organ
vascularization [24,25]. VEGF-A189 and VEGF-A206 are sequestered in the extracellular
matrix (or on cell surface HSPGs), and at least VEGF-A189 has been shown not to partici-
pate in receptor activation [26]. Proteases such as plasmin, urokinase-type plasminogen
activator (uPA), and factor VII-activating protease (FSAP) can release and thus activate
the ECM-bound, longer VEGF-A isoforms [21,27–29]. The cleavage of the primary isoform
VEGF-A165 can also be mediated by various matrix metalloproteinases (MMPs), especially
MMP-3, resulting in smaller, non-heparin-binding products [30]. While such cleavages
do liberate VEGF-A and are necessary for the mitogenic activity of VEGF-A189 [26], they
were reported to reduce the mitogenicity of VEGF-A165 [31]. Unfortunately, there is little
insight into the nature of the molecular handover of HSPG- and ECM-bound VEGF-A to
VEGFR-2 or the VEGFR-2/neuropilin signaling complex [11]. The isoform composition and
the location where the cleavage happens are likely important determinants of the net effect.
The release of cell surface HSPG-bound VEGF-A is perhaps more likely to result in pro-
ductive signaling than the release of ECM-bound VEGF-A. Complementary to the ECM
release by proteolytic cleavage of VEGF-A, enzymatic degradation of the ECM-binding
sites, e.g., of HSPGs by heparinases, or binding site competition by heparin or heparan
sulfate achieves the same release, but without loss of the HBD [27].
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contains a heparin-binding domain homologous to the one in VEGF-A165, but it is 
unknown whether this domain is subject to proteolytic removal. A yet unknown protease 
unmasks the neuropilin-1 binding site of the longer VEGF-B186 isoform, but its target site 
is absent in VEGF-B167 [33]. The cleavage context suggests that thrombin can unmask the 
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is according to the longest shown isoform. VEGF-A is cleaved not only by MMP3 but also in a similar fashion by MMP7,
MMP9, MMP19, and - less efficiently - by MMP1 and MMP16 [30].
Of the four human PlGF isoforms, PlGF-2 and -4 also contain a C-terminal heparin-
binding domain. At least the PlGF-2 HBD can be removed by plasmin [32]. VEGF-B167
also contains a heparin-binding domain homologous to the one in VEGF-A165, but it is
unknown whether this domain is subject to proteolytic removal. A yet unknown protease
unmasks the neuropilin-1 binding site of the longer VEGF-B186 isoform, but its target site
is absent in VEGF-B167 [33]. Th cleavage context suggests that thrombin can unmask
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the neuropilin-1 binding epitope (see Figure 2) [35]. Plasmin cleavage at the same site is
likely but does not result in neuropilin-1 binding due to additional cleavages that remove
important sequences for neuropilin-1 binding [33].
3. The Lymphangiogenic Growth Factors VEGF-C and VEGF-D
The hemangiogenic VEGFs are rendered inactive either through ECM-association
or—as in the case for VEGF-A189—by their C-terminal auxiliary domain. Preventing
receptor activation using inhibitory domains is also characteristic of the lymphangiogenic
VEGFs. Upon secretion, VEGF-C and VEGF-D are kept inactive by their N- and C-terminal
propeptides. Hence, the secreted forms are referred to as pro-VEGF-C and pro-VEGF-D.
The removal of the propeptides requires two concerted proteolytic cleavages and happens
in a very similar fashion for both VEGF-C and VEGF-D (see Figure 3):
1. Protein convertases constitutively cleave VEGF-C before secretion. This intracellular
cleavage occurs between the central VEGF homology domain (VHD) and the C-
terminal propeptide. However, it does not remove the C-terminal propeptide because
it remains covalently attached to the rest of the molecule by disulfide bonds [38–40].
2. The second, extracellular cleavage activates the protein. This cleavage occurs between
the N-terminal propeptide and the VHD [38] and can be mediated by different
proteases. ADAMTS3 mediates VEGF-C activation in the embryonic development of
the mammalian lymphatic system [41–43]. ADAMTS3 is specific for VEGF-C and does
not activate VEGF-D. All other activating proteases target both VEGF-C and VEGF-
D: plasmin [43,44], prostate-specific antigen (KLK3/PSA), cathepsin D (CatD) [45],
and thrombin [46]. The resulting forms of VEGF-C and VEGF-D are referred to as
active, mature, or short forms. However, they differ from each other at their N-termini
because different proteases cleave at different positions within the linker between
the N-terminal propeptide and the VHD (see Figure 4).
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Figure 3. Two proteolytic cleavages are needed to activate VEGF-C and VEGF-D. The first cleavage, by protein convertases,
is constitutive and intracellular. The second is highly regulated and happens after secretion of the pro-forms. Many different
enzymes have been shown to catalyze the second cleavage, but the primary activating protease of VEGF-C in mammalian
developmental lymphangiogenesis is A Disintegrin and Metalloprotease With Thrombospondin Motifs-3 (ADAMTS3).
The immunoprecipitation (IP) of transfected 293T cells with a VEGFR-3(EC)/IgGFc fusion protein pulls down the 58 kDa
full-length VEGF-C, the pro-VEGF-C peptides of 31 kDa and 29 kDa, and the mature VEGF-C. Proteins were resolved under
reducing conditions by SDS-PAGE.
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Interestingly, pro-VEGF-C can competitively block the receptor activation of active,
mature VEGF-C. Its propeptides allow VEGF receptor binding but interfere with receptor
activation. Apart from VEGFR-3, pro-VEGF-C also binds the co-receptor neuropilin-
2. C-terminal propeptide processing exposes two terminal arginines (R226,227), which
contribute to the conserved binding site for neuropilins [47]. Because it is not entirely
clear whether pro-VEGF-C is completely incapable of receptor activation or whether it has
some residual activity, pro-VEGF-C is either a partial agonist or an antagonist of mature
VEGF-C [43].
4. Plasmin and Thrombin
The serine protease plasmin was the first protease that was shown to activate both
VEGF-C and VEGF-D. Plasmin can remove both the N- and the C-terminal propeptides of
VEGF-D to create a mature form containing only the VEGF homology domain [44]. One of
plasmin’s main functions is to degrade fibrin, the main component of blood clots. Thrombin
is the newest addition to the group of VEGF-C/D-activating enzymes. In addition to its
classical role in converting soluble fibrinogen into insoluble fibrin fibrils during blood
clotting, it plays a crucial role in early wound healing [46] by activating VEGF-C, which is
released from α-granules upon platelet aggregation [48]. Hence both thrombin and plasmin
act concertedly to maintain a supply of active VEGF-C over the entire wound healing
period.
However, in vitro, where no feedback loop exists to limit plasmin activity, prolonged
exposure of VEGF-C results in VEGF-C inactivation [43]. In any case, without tissue
damage, inactive prothrombin is not converted into thrombin, and inactive plasminogen
not into plasmin. Therefore, in vivo, VEGF-C activation by thrombin or plasmin is likely
restricted to situations with tissue damage. Using a similar rationale, platelet-rich plasma
has been proposed for the treatment of lymphedema [49] and to promote wound heal-
ing [50]. Some proteomics studies have occasionally missed VEGF-C (as well as VEGF-A)
when examining the platelet proteome, which might result from the relative resistance of
the VEGF cystine knot to digestion with trypsin or similar proteases (unpublished data by
the author). Nevertheless, other analyses and pharmacokinetic studies on anti-VEGF-C
antibodies confirm the early findings of VEGF-C release during blood coagulation [51,52].
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lymphatic development and embryonic survival [14,42], whereas VEGF-D deletion in mice is well tolerated [53]. While
the figure shows the exon structure of VEGF-C and -D, mRNA splice isoforms have only been reported for murine Vegfc [54].
The detected splice variants do not contain the full VEGF homology domain and are therefore not shown here. *Cleavage
site is only predicted based on the amino acid context.
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Plasmin activation of VEGF-C, which has been shown independently by two different
groups [43,44], was not detected in a recent study [46]. Possibly, cleavage products might
not have been recognized by the antibody due to low sensitivity or an absent epitope.
Alternatively, the internal FLAG-tag preceding the cleavage site, which was used to prevent
detection failure due to isoform-specific VEGF-C antibodies, might have interfered with
the activation.
5. ADAMTS3 and the Cofactor CCBE1
ADAMTS3 was identified in the search for the endogenous protease that activates
VEGF-C. Although plasmin had been identified as a VEGF-C-activating protease [44],
it was never seriously considered as a physiological activator of VEGF-C due to its function
in fibrin clot degradation. Moreover, lymphatic phenotypes have never been reported for
the plasminogen knock-out mice [55] or human homozygous functional ablations [56].
In 2009, Alders used homozygosity mapping to identify mutations in the human
CCBE1 gene as a cause of Hennekam Syndrome (HS) [57], which is characterized by
generalized lymphatic dysplasia [58]. When the same Ccbe1 gene was ablated in zebrafish
or mice [59,60], the phenotype was closely phenocopying the Vegfc knock-out [14]. Because
it lacks any protease signature, CCBE1 was assumed to be somehow essential for the VEGF-
C/VEGFR-3 signaling pathway, but not to be the VEGF-C-activating protease itself.
Co-transfection of CCBE1 with VEGF-C demonstrated that CCBE1 enhances the pro-
teolytic processing of VEGF-C in 293T cells, and ADAMTS3 was identified as the re-
sponsible protease by mass spectrometric analysis of a partially purified CCBE1 from
a CCBE1-overexpressing 293T cell line [43]. Based on in vitro data and its high homology
to ADAMTS2, ADAMTS3 had been thought to function in the proteolytic maturation
of procollagens [61]. In mice, Adamts3 deletion does not lead to collagen fibril assem-
bly deficiencies but instead aborts lymphatic development [42]. In humans, mutations
in ADAMTS3 have similarly been shown to result in a lymphatic phenotype, while symp-
toms associated with procollagen cleavage defects are absent [56]. Although these and
other publications have confirmed that both ADAMTS3 and CCBE1 are required for suc-
cessful pro-VEGF-C activation, a direct interaction between VEGF-C and CCBE1 has never
been demonstrated [41,62,63].
Both domains of CCBE1 accelerate the activation of VEGF-C independently [43,54,58],
using different mechanisms. While the N-terminal domain of CCBE1 appears to facilitate
pro-VEGF-C encounters with ADAMTS3, the C-terminal domain acts like a coenzyme [64].
From all VEGF-C-activating enzymes, only ADAMTS3 and PSA/KLK3 have been shown
to be influenced by CCBE1.
6. Species-Specific Differences
Based on sequence similarity, in vitro substrate, and domain organization, ADAMTS2,
-3, and -14 form the aminoprocollagen peptidase subgroup within the ADAMTS protein
family. Species-specific differences in the function of these proteases are seen in vertebrates.
In zebrafish, Adamts3 and Adamts14 compensate for each other, and only the double
Adamts3/Adamts14 knock-out shows a lymphatic phenotype comparable to the Vegfc knock-
out [65]. Such compensation does not happen in Adamts3-deficient mice, which are
completely devoid of functional lymphatics [42]. Whether the observation that human
ADAMTS14 can activate VEGF-C in vitro [65] reflects species differences among mammals
or whether it is an observation without a physiological equivalent is still unknown.
Important species differences have also been reported for the growth factors. In mice,
VEGF-D is dispensable for the development of the lymphatic system [53], while this is
not the case in zebrafish, where it is, e.g., required to form the medial and lateral facial
lymphatics [66,67]. However, even murine VEGF-D reportedly differs from human VEGF-
D in its inability to interact with mouse VEGFR-2 [68]. Exactly the opposite seems to
be the case in zebrafish, where the VEGF-D-VEGFR-3 interaction was reported to be
absent [69], implying that lymphangiogenesis might happen in zebrafish independently of
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VEGFR-3. While direct demonstrations of the substrate specificities of the zebrafish Adamts
proteases are still missing, it appears clear that zebrafish data are not easily extrapolated to
mammals. Unfortunately, the same might be true for the extrapolation of mouse data to
humans.
7. Which Cell Types Provide ADAMTS3 and CCBE1?
Since VEGF-C, ADAMTS3, and CCBE1 are all secreted proteins, immunohistochem-
istry cannot reveal their cellular origin. In the establishment of the early zebrafish lym-
phatics, Pdgfra-positive fibroblast populations appeared to be the source for Vegfc, Adamts3,
Adamts14, and Ccbe1, as identified by single-cell RNA sequencing [65]. While in vitro data
support the notion that fibroblasts are perhaps the dominating source for CCBE1 also
in mammals [63], smooth muscle cells appear to make a significant contribution [14,70].
In some contexts, blood vascular endothelial cells appear to also be an important source of
VEGF-C [71,72] and CCBE1 [73,74]. However, these are crude approximations of the actual
cellular heterogeneity, and in non-homeostatic situations such as inflammation or cancer,
other cell types, e.g., immune cells such as macrophages, are likely significant producers of
both VEGF-C and VEGF-C-activating proteases [75–77].
8. Enigmatic Propeptides
The evolutionary origins of both propeptides of VEGF-C and VEGF-D are unclear.
Unless assuming horizontal gene transfer, they have been conserved for hundreds of mil-
lions of years and can be found in virtually all invertebrate VEGF homologs [78–80]. Apart
from the VEGFs, the only homologous sequences were found within larval silk proteins of
the mosquito genus Chironomus [38,81], resulting in the nickname “silk homology domain”
for the C-terminal propeptide.
Because disulfide bonds link the C- and the N-terminal propeptides of VEGF-C and
VEGF-D, the first, constitutive cleavage by the protein convertase furin (or PC5 or PC7)
does not remove any of the propeptides from VEGF-C or VEGF-D. Both propeptides are
released simultaneously with the activating cleavage between the N-terminal propeptide
and the VEGF homology domain (see Figures 3 and 4). With 80 and 192 amino acid residues,
respectively, the N- and C-terminal propeptides of VEGF-C are significantly longer than
typical propeptides. They also fold independently and are therefore also often referred to
as N- and C-terminal domains. According to the current understanding, the propeptides
serve multiple functions.
1. The heparin-binding C-terminal propeptide mediates ECM-association and cell sur-
face (HSPG) binding [63,82].
2. Both propeptides collaborate in regulating receptor binding and activation [38,43].
While pro-VEGF-C binds VEGFR-3, it cannot (or only marginally) activate VEGFR-3.
Thus, pro-VEGF-C and the individual VEGF-C propeptides, are competitive inhibitors
of mature VEGF-C [43].
3. The presence of the C-terminal propeptide is required for efficient cleavage of the N-
terminal propeptide by ADAMTS3 [63].
Analogous to VEGF-A, the heparin-binding properties are likely necessary for the cor-
rect spatio-temporal distribution of the growth factor and its activity. When the VEGF-C
propeptides are grafted upon VEGF-A, the resulting blood vasculature was denser com-
pared with VEGF-A-induced vasculature [83]. Vice versa, when the C-terminal domain of
VEGF-C was replaced by the heparin-binding domain of VEGF-A, less but larger lymphatic
vessels were generated, which localized preferentially to HSPG-rich structures such as
basement membranes [84]. The heparin binding of VEGF-C is somewhat weaker com-
pared to that of VEGF-A. Although most heparin-binding affinity resides in the C-terminal
propeptide, mature VEGF-C is a heparin-binding growth factor. VEGF-A165 binds tightest
to heparin requiring 0.8 M NaCl for elution, while pro-VEGF-C and mature VEGF-C require
elution concentrations of 0.435 and 0.265 M, respectively [82]. This might explain why both
mature and pro-VEGF-C have a local effect and do not diffuse far [65]. That the C-terminal
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domain mediates the association or embedding of VEGF-C in the extracellular matrix
was speculated shortly after its discovery [38] and was recently directly demonstrated
in vitro [63]. Thus, pro-VEGF-C might be similar in this respect to latent TGF-β [85].
9. Changing Receptor Preferences with KLK3 and Cathepsin D
Based on N-terminal sequencing, two different mature, active forms were identified
for VEGF-C and VEGF-D [38,86]. In the supernatant of 293 cells, the shorter mature form of
VEGF-C was the dominant mature (“major”) form, while, for VEGF-D, the longer mature
form was dominant. While this indicated early on that different proteases are involved
in VEGF-C and VEGF-D activation, it remained unknown which proteases were involved.
In 2011, Leppänen et al. found that the shorter (“minor”) form of active VEGF-D was not
able to activate VEGFR-3 [87]. This finding was surprising as the activation of VEGFR-3
is considered a prerequisite of being lymphangiogenic. It also indicated for the first time
that a lymphangiogenic growth factor can be converted into an angiogenic growth factor
by proteolysis. At the same time, it explained why VEGF-D had been identified in some
experimental settings as a powerful angiogenic growth factor [88]. While other research
confirmed the disparity between VEGF-C and VEGF-D in terms of protease utilization for
activation [41], the exact nature of the VEGF-D-activating proteases remained unknown
until 2019 when Jha et al. tested whether their newly discovered VEGF-C-activating
proteases PSA and Cathepsin D (CatD) could also activate VEGF-D [45]. In fact, CatD
was able to generate the VEGFR-2-specific mature form of VEGF-D, which Leppänen et al.
had described in 2011 [87]. Despite this, it remains to be shown which protease activates
VEGF-D in vivo and whether there is a “physiological protease” equivalent to the VEGF-C-
activating ADAMTS3. Perhaps VEGF-D is solely activated in non-homeostatic situations
such as tissue damage. Nevertheless, also without any pathological challenge, VEGF-D
knock-out mice display subtle alterations in some lymphatic networks [53,89]. These minor
phenotypes could result from a lack of activated VEGF-D, but equally well from a lack of
pro-VEGF-D (assuming it has some low level of activity) or possibly VEGF-C/VEGF-D
heterodimers.
When comparing the effects of different VEGF-C- and VEGF-D-activating proteases [45],
two trends are visible, which are summarized in Figure 5:
1. The shorter the N-terminus of the resulting mature growth factor, the lower its
receptor binding affinity and receptor activation potential.
2. N-terminal shortening affects VEGF-C and VEGF-D very differently. While VEGF-C
rapidly loses its potential to activate VEGFR-2 (through activation by ADAMTS3 or
PSA), VEGF-D maintains much of its VEGFR-2 binding and activation potential. Vice
versa, VEGF-D rapidly loses its VEGFR-3 binding and activation potential, whereas
VEGF-C maintains much of it when processed to a similar degree.
3. Both VEGF-C and VEGF-D are completely inactivated with respect to their receptor
tyrosine kinase activity by complete removal of their N-terminal helices, which, e.g.,
can be achieved by prolonged exposure to plasmin.
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10. Secondary Processing and Inactivation
At least in itro, the longer f ms of activated VEGF-C VEGF-D can undergo ad-
ditional leavages, further shortening the N-terminus d modifying the receptor binding
capabilities, e.g., C tD can remove the lymphangiogenic potential from plasmin-activated
VEGF-D and the angiogenic potential from ADAMTS3-activated VEGF-C [45]. Finally,
a leav ge by plasmin can inactivate VEGF-C a d VEGF-D. However, such secondary
(or tertiary) processing has not yet been demonstrated in vivo.
11. Other Cleavages
The activating, N-terminal cleavage of VEGF-D has also been proposed to be mediated
by the protein convertases furin or PC5 [39]. While this is certainly a possibility, it seems
unlikely that this represents a significant VEGF-D activation mechanism in vivo. The ma-
ture VEGF-D produced in furin-deficient Lovo cells upon transfection with furin could well
be due to any other endogenous protease in Lovo cells. The requirement for furin in this
system might occur if C-terminal furin processing was a prerequisite for the activating
N-terminal cleavage. However, such a prerequisite seems not to exist for VEGF-C [41].
Vice versa, plasmin [44] or PSA [45] have not only been shown to perform the N-terminal
processing of VEGF-D, but also the C-terminal processing. Nonetheless, this is also likely
irrelevant since the protein convertases cleave constitutively inside the cell before VEGF-D
ever has the chance to encounter plasmin or PSA.
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12. Possible Involvement in Reproduction and Wound Healing
That VEGF-C is a possible substrate for kallikrein-like peptidases had been proposed
before [90], but the identification of KLK3 (also known as prostate-specific antigen, PSA)
was, nevertheless, surprising, especially because KLK3 is largely confined to sperm plasma.
The presence of VEGF-C, CCBE1, and a VEGF-C-activating protease in sperm plasma [45]
is too tempting not to speculate about a possible function of VEGF-C for reproductive
biology, but such has not been confirmed yet. Mutations in KLK3 affect male fertility [91],
but this is unsurprising since the main biological function of KLK3 is the degradation of
gel-like seminogelins, which releases the sperm cells [92]. VEGF-A, which is also present
in sperm plasma [93,94], had a modest effect on sperm motility [95]. Therefore, similar
experiments were attempted with VEGF-C yielding very variable results (unpublished
data by the author), perhaps due to the logistically challenging experimental setup.
Like KLK3, cathepsin D was also identified after an exhaustive analysis of bodily
fluids for possible VEGF-C-cleaving activities [45]. VEGF-C is deposited by virtue of its
C-terminal domain into the extracellular matrix and released by proteases [63]. Because
VEGF-C accelerates wound healing [96,97], it appears possible that Cathepsin D provided
by wound licking might activate latent ECM-embedded pro-VEGF-C. Thus, an instant
angiogenic, lymphangiogenic, and immunologic stimulus would be provided. Compared
to a single gene in humans, KLK1 was several times duplicated in rodents, leading to at
least 23 KLK1 orthologs (some of which being pseudogenes), and some researchers believe
that the evolutionary pressure to heal bite wounds rapidly and efficiently was driving this
expansion [98].
13. Activating VEGF-C and VEGF-D in Cell Culture
While there are several cell lines that endogenously express VEGF-C or VEGF-D (most
notably PC-3, from which VEGF-C was originally identified [99]), almost all experiments
that require the expression of these growth factors have been performed by cDNA trans-
fection. When the full-length wildtype cDNAs are used, the inactive pro-forms dominate
in the cell culture supernatant of most cell lines (see Figure 3). Cells that express both
CCBE1 and ADAMTS3 (such as cell lines derived from 293 cells) will process at least some
of the pro-VEGF-C into mature, active VEGF-C. This endogenous background activation is
sufficient to detect mature VEGF-C even in the absence of added proteases (see Figure 3).
If these background activation bands are missing from a Western blot, the detection is likely
not very sensitive, or something interferes with the physiological activation of VEGF-C
by ADAMTS3. The degree of processing is relatively difficult to predict and appears to
depend on cell density, stress level, cell culture medium, and—most importantly—VEGF-C
expression levels. In any case, the processing is inefficient, and the 293T cell line that was
used to generate the gel image in Figure 3 is among the cell lines that most efficiently
activate VEGF-C endogenously.
14. Truncated cDNAs Are Used to Recombinantly Express Pre-Activated VEGF-C and
VEGF-D
Therefore, when larger amounts of active VEGF-C are required, the solution has been
to express a mutant VEGF-C cDNA, from which the sequences coding for the propep-
tides have been deleted (“∆N∆C-VEGF-C”). All recombinant, commercially available
VEGF-C and VEGF-D proteins are produced in this fashion. However, because the signal
peptide’s cleavage context is disturbed, the N-terminus of the resulting protein can differ
from the endogenously activated VEGF-C. Only N-terminal sequencing can reveal which
form of VEGF-C is present. With few exceptions (R&D Systems), vendors do not provide
this information. The same is true for many scientific publications that use truncated
cDNAs to express VEGF-C or VEGF-D. While it is possible to predict the signal peptidase’s
likely cleavage position, only N-terminal sequencing can give a definite answer. Many of
the early experiments involving recombinant VEGF-D have used a truncated cDNA that
results in a VEGF-D form, which is an intermediate between the VEGFR-2-monospecific
Biology 2021, 10, 167 12 of 23
and the VEGFR-2-/VEGFR-3-bispecific endogenous VEGF-D forms, making it difficult to
interpret the data [68]. However, after the recent identification of the cleaving proteases, it
became possible to generate specific mature forms by co-transfection of the protease with
the full-length wildtype growth factor cDNA [43,45]. However, when using pre-activated
forms of VEGF-C or VEGF-D, one should remember that it is unclear whether these exist
as independent species in vivo. Pro-VEGF-C efficiently binds VEGFR-3 in the context of
neuropilin-2, and the “in-situ” activation of pro-VEGF-C (while being bound to VEGFR-3)
might be the standard mode of activation [43,63]. Interestingly, a transgenic mouse express-
ing pre-activated (∆N∆C-VEGF-C) VEGF-C under the control of the keratin-14 promoter
did not show the characteristic lymphatic phenotype in the skin as mice expressing VEGF-C
from a full-length cDNA under the same promoter (unpublished data by the author) [100].
15. Modulation of Proteolytic Processing
Protease inhibitors have a veritable track record as drugs, targeting, e.g., viral pro-
teases in AIDS and other viral infections [101], neutrophil elastase in lung diseases [102],
and angiotensin-converting enzyme in cardiovascular diseases [103]. The opposite
approach—promoting proteolysis—has also resulted in life-saving treatments, e.g., the use
of tissue plasminogen activator (tPA) to dissolve blood clots in the immediate treatment of
ischemic stroke [104].
Given the importance of the lymphatic system in many diseases [105], both VEGF-C
and VEGF-D are likely worthwhile drug targets. Lymphedema, the swelling of organs or
tissues due to an absent, hypoplastic, dysfunctional, or overloaded lymphatic network,
represents a major clinical challenge because no causal, only symptomatic, treatments
are available. The concept of pro-lymphangiogenic therapy to treat lymphedema has
progressed to clinical trials using adenoviral VEGF-C gene therapy [106]. In these trials,
pro-VEGF-C is produced from a full-length cDNA, relying on endogenous proteases for
its activation. Using an adenovirus that produces pre-activated VEGF-C from a truncated
cDNA would remove the requirement for endogenous proteases, which might or might not
be a bottleneck. Alternatively, co-delivering CCBE1 and/or ADAMTS3 using an adenovirus
cocktail could also boost the amount of active VEGF-C. However, the full-length cDNA of
VEGF-C has been preferred over the truncated cDNA in most preclinical studies. Removing
the N-terminal propeptide from VEGF-C results in an unpaired cysteine residue in VEGF-
C’s receptor-binding domain. This extra cysteine residue is conserved among all VEGF-C
and VEGF-D orthologs but is absent from all other VEGF family members [99,107,108].
Therefore, when active VEGF-C or VEGF-D are expressed directly from a truncated cDNA,
the monomeric growth factor can be the predominant species [103]. Monomeric growth
factor exposes the dimerization interface to the environment and is predicted to interfere
with receptor dimerization and activation. For crystallization studies, the extra cysteine
residues can be mutated to promote dimerization [8,82], but the use of mutated proteins as
biological drugs requires solid justification.
A continuous low-level supply with VEGF-C appears necessary to maintain the struc-
ture and functionality of heavily engaged lymphatic networks [70,109,110]. As an alter-
native to VEGF-C itself, a highly specific VEGF-C-activating protease might equally be
suitable if it can activate endogenous ECM-embedded VEGF-C. Such VEGF-C activation
might both act via stimulating lymphatic pumping [111] and by inducing a compensatory
expansion of the lymphatic network [112].
In inflammatory and infectious diseases, the lymphatic network must manage the fluid
balance during inflammatory swelling. Perhaps more importantly, there is increasing
evidence that both innate and adaptive immunological responses are crucially dependent
on the lymphatics during all stages of an immune response [113,114]. Thus, the activation of
VEGF-C could be used as a generic means to boost any immune response like an adjuvant.
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16. Proteolytic Activation of VEGF-C and VEGF-D in Cancer
The crucial role of tumor-associated lymphatics for metastasis was recognized early
on [115–118], and VEGF-C/VEGF-D inhibition has been proposed to therapeutically block
metastasis. Since the tumor-promoting effects of VEGF-C and VEGF-D likely require
proteolytic processing, inhibition could not only target the growth factors or receptors, but
also the activating proteases. In vitro, VEGF-C-expressing MCF-7 and MDA-MB-435 cells,
which have been used for xenograft tumor models, are inefficient in activating the growth
factor [115,117]. Therefore, it is assumed that the activating proteases are supplied in these
xenograft models by the stromal tumor compartment, perhaps by fibroblasts, inflammatory
or endothelial cells [119,120]. Harris et al. generated a mutated form of VEGF-D, which is
resistant to proteolytic activation They showed that this mutant could not promote tumor
growth and lymph node metastasis in a mouse tumor model [121].
Tumor cells can migrate and form distant metastases via two distinct pathways: via
blood vessels (hematogenic spread) and via lymphatics (lymphogenic spread). VEGF-C and
VEGF-D can stimulate both pathways. By stimulating lymphangiogenesis into the tumor
periphery (and occasionally also into the tumor), these growth factors maximize the access
of tumor cells to the lymphatic vasculature. VEGF-C further appears to actively prepare
the downstream lymph nodes for arriving cancer cells [122]. If the tumor happens to
express suitable proteases, it is likely that VEGF-C (and even more so VEGF-D) is activated
into forms that mimic VEGF-A but which are not inhibited by current anti-angiogenic
treatments [123]. Such angiogenic redundancy might be one of the reasons why VEGF-A
treatment is much less universal as initially anticipated, and why in amenable cancers,
initial treatment success is usually followed by the development of resistance [124].
However, anti-lymphangiogenic therapy is a double-edged sword [125] because
tumor-associated lymphatics are crucially important for the immune response against
the tumor. When VEGF-C action was blocked in a mouse tumor model treated with
immunotherapy, the mice receiving the anti-VEGF-C treatment died earlier than those
who did not receive the treatment [126]. Similarly, in a mouse glioblastoma model, VEGF-
C could amplify the CD8+ T cell response against the tumor [127]. In order to be able
to successfully target VEGF-C in cancer, a thorough understanding of the underlying
molecular mechanisms is needed. This understanding might ultimately allow us to sepa-
rate the metastasis-enhancing function of VEGF-C from the immune-response-enhancing
function of VEGF-C. Such separation might involve activating VEGF-C into a largely
VEGFR-3-specific form eliminating some (but not all) of VEGF-C’s angiogenic features.
However, since trafficking via the lymphatic neovasculature is integral to both tumor cell
dissemination and immune response, separating these two functions appears unlikely to be
feasible at the level of the VEGF-C/VEGFR-3 signaling axis. However, our understanding
of the underlying molecular events is highly incomplete as we do not even know which
specific proteases are activating VEGF-C in human cancers. A high-probability guess is
that different proteases are involved depending on the cancer type.
17. Blocking VEGF-C and VEGF-D Activation
The proteolytic processing of VEGF-C and VEGF-D has been so far experimentally
blocked only by mutagenesis of the cleavage sites. Furin and related protein convertases
cleave VEGF-C after the double arginines (R226,227). Joukov et al. reported that mutating
these arginines into serines (R226,227S) mostly blocked VEGF-C processing [38]. This is
surprising since the N-terminal cleavage site should have been still subject to proteolytic
attack because the first, constitutive C-terminal cleavage and the second, N-terminal
cleavage were subsequently shown to occur independently of each other [41]. To generate
an even more activation-resistant form of VEGF-D, Harris et al. mutated, in addition to
the C-terminal cleavage site, the major N-terminal cleavage site and reported, similar to
Joukov et al., almost complete abrogation of VEGF-D activation [121]. It is unclear why
the unmutated minor N-terminal cleavage site in this protein did not result at least in partial
activation. After all, in the same 293 EBNA cell line, the minor N-terminal cleavage site
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had been shown to account for approximately 20% of the activated protein [86]. However,
a therapeutic effect might not require full inhibition of cleavage because pro-VEGF-C
acts as an antagonist of mature VEGF-C, and therefore, a low level of cleavage might be
acceptable [43].
18. Lymphedema and Genetic Lesions Affecting the Activation of VEGF-C
Lymphedema is traditionally categorized into either primary or secondary lym-
phedema. Most lymphedema cases fall into the secondary category, resulting from various
external insults to the lymphatic system, surgery and infection being most common [128].
On the other hand, primary lymphedema results from genetic lesions, which can be inher-
ited or acquired during development. The latter makes them more challenging to identify
since the genetic lesion might be present only in a subset of cells or organs [129]. For
roughly 40% of primary lymphedema cases, the underlying genetic lesion can be identi-
fied, and a clinical guide for this process has been established [130]. However, secondary
lymphedema also has a genetic component [131–133], and thus, primary and secondary
lymphedema should be considered the endpoints of a continuous spectrum.
All mutations that disrupt the VEGF-C/VEGFR-3 signaling pathway result in hered-
itary lymphedema (Figure 6). While the most common type of hereditary lymphedema
is caused by a mutation in the VEGF-C receptor [134,135], any signaling pathway compo-
nents can be affected, including the proteolytic activation of VEGF-C. Thus, in human lym-
phedema patients, disease-causing mutations have been found in VEGF-C itself [136,137],
in its activating protease ADAMTS3 [62,63], and the cofactor CCBE1 [57,138]. Genetic le-
sions in FAT4 result in a phenotype closely resembling the phenotypes caused by mutations
in CCBE1 or ADAMTS3. Only recently, Hennekam Syndrome was split into three different
subtypes depending on the underlying genetic lesion (Hennekam Syndrome Type 1, 2,
and 3).
Interestingly, the primary function of FAT4 is likely unrelated to VEGF-C processing
or VEGFR-3 signaling. Instead, it appears necessary for the flow-dependent establishment
of lymphatic endothelial cell polarity [139]. However, in vitro analysis of FAT4 has been
hampered because it is a very large protein with a highly repetitive structure [140]. Besides
VEGF-C/VEGFR-3 signaling pathway genes known to be compromised in hereditary
lymphedema or Hennekam Syndrome, Table 1 also lists selected other genes known
to be causative for hereditary diseases featuring lymphedema as a cardinal symptom.
Furthermore, Table 1 contains, in addition to ADAMTS3, the genes of all other proteases
reportedly able to activate VEGF-C and VEGF-D. For all of these, genetic lesions have been
described, but lymphedema has not been associated with any of them, arguing that they
are not required for the development of the lymphatic system.
Table 1. Important genes for lymphatic development and/or VEGF-C activation, which are involved in human hereditary
disorders. Mutations in the VEGF-C-activating proteases are not associated with any lymphatic phenotype except for
ADAMTS3, arguing that only ADAMTS3 is essential for lymphatic development.
Gene Protein Human Disease (OMIM) Remarks
Genes within the VEGF-C/VEGFR-3 signaling pathway; for clinical details see [130], and for molecular details [141]
VEGFC Vascular Endothelial GrowthFactor-C (VEGF-C)
Hereditary lymphedema type 1D
(615907)
VEGF-C is the primary growth
factor for lymphatic endothelial
cells.
FLT4 Vascular Endothelial Growth FactorReceptor-3 (VEGFR-3)
Hereditary lymphedema type 1A
(Milroy disease, 153100)
VEGFR-3 is the primary receptor
of VEGF-C.
CCBE1 Collagen and calcium-binding EGFdomain-containing protein 1
Hennekam
lymphangiectasia-lymphedema
syndrome type 1 (235510)
Enhances the processing of
VEGF-C by ADAMTS3 and KLK3.
ADAMTS3 A disintegrin and metalloproteinasewith thrombospondin motifs 3
Hennekam
lymphangiectasia-lymphedema
syndrome type 3 (618154)
ADAMTS3 catalyzes the final step
in the activation of VEGF-C.
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Table 1. Cont.
Gene Protein Human Disease (OMIM) Remarks
Genes coding for proteases that can activate VEGF-C and/or VEGF-D (no lymphatic phenotype reported)
ADAMTS14 A disintegrin and metalloproteinasewith thrombospondin motifs 14
Association with age of onset
in tendinopathy [142]
ADAMTS14 can activate VEGF-C
in vitro [65].
KLK3 Kallikrein-like peptidase 3,Prostate-specific antigen (PSA) Association with human fertility [91]
KLK3/PSA is most commonly
known as a prostate cancer
marker [143].




F2 Prothrombin/Thrombin Hereditary thrombophilia type 1(188050)
Specific F2 mutations increase




(VEGF-) induced endothelial cell
proliferation [146].
PLG Plasminogen/Plasmin Plasminogen deficiency type 1(217090)
PLG deficiency leads to
pathological fibrin deposition but
no increased risk of thrombosis
[147].
Selected other “lymphedema” genes; for a comprehensive listing, see [130]
FOXC2 Forkhead box protein C2 Lymphedema distichiasis syndrome(153400)
The maturation of lymphatic
vessels and the formation of
lymphatic valves requires FOXC2
[148,149].
GJC2 Connexin 47 Hereditary lymphedema type 1C(613480)
CJC2 is a gap junction protein that
enables communication between
lymphatic endothelial cells [150].
FAT4 Protocadherin Fat 4
Hennekam
lymphangiectasia-lymphedema
syndrome type 2 (616006)
FAT4 is required for lymphatic
endothelial cell polarity and
might influence VEGFR-3
signaling [139].
Van Maldergem syndrome type 2
(615546)
Van Maldergem syndrome 2 has
overlapping features with
Hennekam syndrome type 2 but
none or only infrequent
lymphatic involvement [151].
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organs. Since at least a fraction of the VEGF-C appears to originate from blood vascular 
endothelial cells, a vascular-targeted repair appears possible [154]. If sufficiently specific, 
the systemic delivery of regulatory factors such as CCBE1 or ADAMTS3 might 
alternatively result in a widespread low-level activation (“molecular nudging”) of 
Figure 6. Genes of the VEGF-C/VEGFR-3 signaling pathway known to be involved in hereditary
lymphedema. Although different components of the signaling pathway can be affected, the largest
fraction of cases are caused by mutations in the FLT4 gene, which codes for the VEGF-C receptor
VEGFR-3.
19. Outlook: olecular Nudging
With the first uccesses in Crispr-Cas clini al tri ls, genetic d fi ienc es within the VEGF-
C/VEGFR-3 signaling pathways appear at least theoretically amen ble for repair. However,
even cutting-edge trials limit themselves at the mom nt to cells that can be easily modified
ex vivo (blood diseases such as ickle cell di ease and β-thalassemia) [152] or to very
l calized targets [153]. We are still far from a systemic repair of solid tissues, which wo ld
be needed since the lymphatic system penetrates al ost all our bodie ’ organs. Since
at le st a fraction of he VEGF-C appears to originate fr m blood vascular endothelial
c lls, a vascular-targeted repair app ars ossible [154]. If ufficiently specifi , the syst mic
delivery of regulatory factors s ch as CCBE1 or ADAMTS3 might alternatively result
in a widespread low-level activation (“molecular nudging”) of end genous VEGF-C and
a therapeutic effect. While such interventions do not reverse developmental routes already
taken, they still might significantly improve life quality.
For cancer, being the prototype of a moving drug target, molecular nudging is not
likely to have any impact. While a multitargeted anti-VEGF-A/-C/-D therapy might
result in improved survival, any progress in this area will likely be incremental since using
alternative tumor angiogenesis factors is only one of many escape mechanisms that tumors
can deploy [124].
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